Results 71 to 80 of about 1,414 (186)
Driving Innovation: The Impact of National Health Policies on Optometry Research in East Asia
The International Journal of Health Planning and Management, Volume 41, Issue 1, Page 37-46, January 2026.ABSTRACT This study examines the optometric research landscape in three East Asian countries—China, Japan, and Korea—analysing how research trends align with each country's national health strategies. By evaluating published articles and reviews from national journals between 2006 March 2025, we identify key areas of focus, including paediatric ...
Jihye Ahn, Moonsung Choi
wiley +1 more source
Journal of Ophthalmology, Volume 2026, Issue 1, 2026.Objective To investigate associations between baseline structural and functional biomarkers and 6‐month post‐treatment best‐corrected visual acuity (BCVA) among patients with diabetic macular edema (DME) receiving intravitreal anti‐VEGF therapy. Methods Data from patients treated at Hebei Eye Hospital between December 2022 and January 2024 were ...
Yi Cai +8 more
wiley +1 more source
Isoelectric point measurements of conbercept with PNGase F treatment at 0, 7 and 48 h.
, 2013 Isoelectric point measurements of conbercept with PNGase F treatment at 0, 7 and 48 h.
Jian Huang (7250) +7 more
core +1 more source
The binding efficiency comparison of conbercept and Avastin with VEGF isoforms and PlGF by ELISA.
, 2013 Conbercept present in figure by using an alias as KH902.
Qin Wang (109812) +6 more
core +1 more source
Frontiers in Pharmacology, 2022 Background: The study concerning the influence of Conbercept, which is an anti-Vascular endothelial growth factor (VEGF) agent, in intraocular pressure (IOP) spike is limited and warrants further investigation.
Yunyan Hu +8 more
doaj +1 more source
BMC Ophthalmology, 2021 Background To evaluate the 12-month efficacy and safety of intravitreal conbercept for myopic choroidal neovascularization (CNV). Methods A retrospective, observational study.
Xin Nie +3 more
doaj +1 more source
Clinical &Experimental Ophthalmology, Volume 53, Issue 9, Page 1202-1217, December 2025.ABSTRACT Retinopathy of prematurity (ROP) remains a major cause of preventable blindness in premature infants worldwide, with increasing incidence due to advancements in neonatal care. Management of ROP has been revolutionised by anti‐vascular endothelial growth factor (anti‐VEGF) treatments.
Kyle V. Marra +3 more
wiley +1 more source
A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
Scientific Reports, 2018 AbstractIntravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations.
Yong Cheng +4 more
openaire +3 more sources
Peptide mapping of conbercept without (up) and with PNGase F treatments (bottom).
, 2013 Peptide mapping of conbercept without (up) and with PNGase F treatments (bottom).
Jian Huang (7250) +7 more
core +1 more source
Acta Ophthalmologica, Volume 103, Issue 7, Page 741-763, November 2025.Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler +17 more
wiley +1 more source